Education
About Us
Working with TipRanks
Follow Us
Iovance Biotherapeutics Inc (IOVA)
NASDAQ:IOVA
IOVA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.70 - $13.88
Previous CloseN/A
Volume2.95M
Average Volume (3M)9.43M
Market Cap
$1.04B
Enterprise Value$1.99B
Total Cash (Recent Filing)$311.80K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.24
Next Earnings
May 08, 2025EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding333,934,400
10 Day Avg. Volume8,540,006
30 Day Avg. Volume9,434,006
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-5.49
Forecast
1Y Price Target
$18.17Price Target Upside480.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
---
Iovance Biotherapeutics News
---
Bulls Say, Bears Say
Bulls Say
Product DemandStrong Proleukin sales indicate rapid and sustained demand for AMTAGVI, suggesting potential growth in the upcoming year.
Revenue GuidanceManagement reiterated 2025 revenue guidance of $450-475MM, which will be driven by continued expansion within ATCs.
Sales GrowthProleukin revenues in 4Q24 were $25.0MM due to the activation and subsequent stocking of a third specialty distributor, with management expecting demand to continue growing.
Bears Say
Revenue Expectations4Q24 revenues from Amtagvi were lower than both the analyst's and consensus estimates.
Revenue MissQ4 Amtagvi revenue of $49MM missed consensus of $55MM by 11%.
Revenue PerformanceThe stock is down approximately 20% post-close because of perceived Amtagvi revenue slowdown.
---
Ownership Overview
0.30% Insiders
17.00% Mutual Funds
0.17% Other Institutional Investors
66.88% Public Companies and
Individual Investors
IOVA FAQ
What was Iovance Biotherapeutics Inc’s price range in the past 12 months?
Iovance Biotherapeutics Inc lowest stock price was $2.70 and its highest was $13.88 in the past 12 months.
What is Iovance Biotherapeutics Inc’s market cap?
Iovance Biotherapeutics Inc’s market cap is $1.04B.
When is Iovance Biotherapeutics Inc’s upcoming earnings report date?
Iovance Biotherapeutics Inc’s upcoming earnings report date is May 08, 2025 which is today.
How were Iovance Biotherapeutics Inc’s earnings last quarter?
Currently, no data Available
Is Iovance Biotherapeutics Inc overvalued?
According to Wall Street analysts Iovance Biotherapeutics Inc’s price is currently Undervalued.
Does Iovance Biotherapeutics Inc pay dividends?
Iovance Biotherapeutics Inc does not currently pay dividends.
What is Iovance Biotherapeutics Inc’s EPS estimate?
Iovance Biotherapeutics Inc’s EPS estimate is -0.24.
How many shares outstanding does Iovance Biotherapeutics Inc have?
Iovance Biotherapeutics Inc has 333,934,400 shares outstanding.
What happened to Iovance Biotherapeutics Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Iovance Biotherapeutics Inc?
Currently, no hedge funds are holding shares in IOVA
---
Iovance Biotherapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.17 (480.51% Upside)
$18.17 (480.51% Upside)
Blogger Sentiment
Bullish
IOVA Sentiment 75%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 4.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $503.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.66%
12-Months-Change
Fundamentals
Return on Equity
-57.48%
Trailing 12-Months
Asset Growth
16.67%
Trailing 12-Months
Company Description
Iovance Biotherapeutics Inc
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
---
IOVA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call demonstrated strong revenue performance and positive market adoption for Amtagvi, with significant highlights in manufacturing capacity and pipeline progress. However, high operating costs and the need for acceleration in adoption at ATCs present challenges.Read More>---
IOVA Stock 12 Month Forecast
Average Price Target
$18.17
▲(480.51% Upside)
Technical Analysis
Pacira Pharmaceuticals
―
Ardelyx
―
Viridian Therapeutics
―
Syndax Pharmaceuticals
―
89bio
―
---